BioCentury | Feb 23, 2015
Analyst Picks & Changes

Analyst picks & changes

...downgraded, noting that consensus expectations of anemia drug Injectafer ferric carboxymaltose and hyperphosphatemia drug Velphoro sucroferric oxyhydroxide...
...assumes Injectafer end-user sales will increase from $50M in 2014 to $500M in 2018, and Velphoro...
BioCentury | Feb 16, 2015
Clinical News

Velphoro sucroferric oxyhydroxide regulatory update

...in Healthcare (IQWiG) said in an early benefit assessment that the added benefit of Velphoro sucroferric oxyhydroxide...
...The oral iron-based phosphate binder is marketed in the EU and U.S. for the indication. Velphoro...
...Ltd. (SIX:GALN), Bern, Switzerland Kissei Pharmaceutical Co. Ltd. (Tokyo:4547), Nagano, Japan Product: Velphoro sucroferric oxyhydroxide ( PA21...
BioCentury | Feb 5, 2015
Finance

PPPs holding steady

BioCentury's annual analysis of public-private partnerships and early stage venture financing activity shows that the model of using PPPs to foster academic innovation is holding fast, and that academia is an active driver behind the...
BioCentury | Oct 27, 2014
Analyst Picks & Changes

Analyst picks & changes

...primarily based on the view that consensus forecasted an "overly bullish" U.S. launch of Velphoro sucroferric oxyhydroxide...
...ferric carboxymaltose. Renterghem said the market now better reflects more realistic near-term expectations. Galenica launched Velphoro...
BioCentury | Sep 1, 2014
Clinical News

Velphoro sucroferric oxyhydroxide regulatory update

...The European Commission approved Velphoro sucroferric oxyhydroxide from Vifor-Fresenius Medical Care Renal Pharma Ltd. to control serum...
...pricing information. The oral iron-based phosphate binder is marketed for the indication in the U.S. Velphoro...
...Ltd. (SIX:GALN), Bern, Switzerland Kissei Pharmaceutical Co. Ltd. (Tokyo:4547), Nagano, Japan Product: Velphoro sucroferric oxyhydroxide ( PA21...
BioCentury | Aug 28, 2014
Company News

European approval for Velphoro

...The European Commission approved Velphoro sucroferric oxyhydroxide from Vifor-Fresenius Medical Care Renal Pharma Ltd. to control serum...
...peritoneal dialysis. The oral iron-based phosphate binder is marketed for the indication in the U.S. Velphoro...
BioCentury | Jul 14, 2014
Clinical News

Velphoro sucroferric oxyhydroxide regulatory update

...EMA’s CHMP issued a positive opinion recommending approval of Velphoro sucroferric oxyhydroxide from Galenica’s Vifor Pharma Ltd...
...U.S., where it is approved to control serum phosphorus levels in CKD patients on dialysis. Velphoro...
...Ltd. (SIX:GALN), Bern, Switzerland Kissei Pharmaceutical Co. Ltd. (Tokyo:4547), Nagano, Japan Product: Velphoro sucroferric oxyhydroxide ( PA21...
BioCentury | Jan 13, 2014
Finance

Buyside View XXII: 'Grown up' means growth

...Major depressive disorder (MDD) U.S. Fresenius SE & Co. KGaA (Xetra:FRE; OTCQX:FSNUY)/Galenica Ltd. (SIX:GALN) Velphoro sucroferric oxyhydroxide...
BioCentury | Jan 6, 2014
Finance

4Q Stock Wrap-Up: All's well that ends well

...treat varicose veins Fresenius SE & Co. KGaA (Xetra:FRE; OTCQX:FSNUY)/Galenica Ltd. (SIX:GALN) FDA approves Velphoro sucroferric oxyhydroxide...
BioCentury | Dec 9, 2013
Clinical News

Velphoro sucroferric oxyhydroxide regulatory update

...and its specialty pharma business, Vifor Pharma Ltd., said FDA approved an NDA for Velphoro sucroferric oxyhydroxide...
...the oral iron-based phosphate binder is under EMA review, with a decision expected in 1H14. Velphoro...
...Ltd. (SIX:GALN), Bern, Switzerland Kissei Pharmaceutical Co. Ltd. (Tokyo:4547), Nagano, Japan Product: Velphoro sucroferric oxyhydroxide ( PA21...
Items per page:
1 - 10 of 24